Top Markets
#1 Glidr Glidr +51.75%
#2 DOVU DOVU +47.62%
#3 Akedo Akedo +43.85%
#4 Velvet Velvet +39.70%
#5 Black Phoenix Black Phoenix +34.25%
#6 Cross Cross +26.33%
#7 Perle Perle +18.76%
#8 Cysic Cysic +18.58%
#9 Bitway Bitway +15.04%
#10 QANplatform QANplatform +14.82%
Coin of the day
Glidr Glidr
설정
언어
한국어
통화
USD
테마
Aceragen, Inc. Aceragen, Inc.

Aceragen, Inc.

ACGN
주식 순위 #39035
Aceragen, Inc., a biopharmaceutical firm in its clinical development phase,... Aceragen, Inc., a biopharmaceutical firm in its clinical development phase, operates out of Exton, Pennsylvania, and was founded in 1989. The company, which transitioned from Idera Pharmaceuticals, Inc. and adopted its current name in January 2023, concentrates on the discovery, advancement, and bringing to market of therapeutic agents for uncommon lung and autoimmune conditions exclusively within the United States. Its product development pipeline includes ACG-701, currently undergoing Phase 2 clinical evaluation for both cystic fibrosis pulmonary exacerbations and melioidosis, as well as ACG-801, which is being developed to address Farber disease. Moreover, Aceragen maintains a partnership and option agreement with Scriptr Global, Inc. This collaboration aims to pinpoint, research, and cultivate gene therapy options intended for the management, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia.
주가
$0.38
마지막 동기화: 2023-09-01
시가총액
$677.16K
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Aceragen, Inc. (ACGN)

카테고리

Healthcare
Aceragen, Inc. (ACGN)의 매출
Aug 2026 기준 매출 TTM: 0
Aceragen, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Aceragen, Inc.의 수익 기록 (2026 ~ 2026)
매년 말 매출
연도 매출 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE